drugset
drugset / Trial / NCT04774419

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

NCT04774419 ↗

Phase 2 Recruiting 62 enrolled Memorial Sloan Kettering Cancer Center Tesaro, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.

Timeline

Start
2021-04-02
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dostarlimab Monoclonal antibody 500 mg Intravenous

Indications

endometrial cancer